IntelliPharmaCeutics Corp. – FDA 483, Jun 14, 2019
An FDA inspection of Intellipharmaceutics Corp., a drug manufacturer in Toronto, Ontario, revealed significant deficiencies across multiple systems. Observations included inadequate equipment cleaning and validation, compromised data integrity in laboratory computer systems, and an improperly designed sampling booth. The firm also failed to follow written procedures for complaint investigations and environmental monitoring, and lacked scientifically sound sampling plans and hold time justifications.
ID · 403cc2b4-473f-41ed-aa24-59a66e7b0054
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.